A Phase 2/3 interventional study of Epinephrine Injection in Pediatric Out-of-Hospital Cardiac Arrest, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Recruiting at 1 site in Canada. Open to participants aged 1 Day to 17 Years. Per ClinicalTrials.gov, last updated 2025-03-11.
Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Phase 2/3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Heart Arrest with a site in Canada — 10 open to participants now, 13 under way, 1 of them phase 3. Heart Arrest · Canada.
Among the 65 studies in Heart Arrest with a site in Canada, this one is the 22nd largest by planned enrollment of the 46 interventional ones that give a count, is the only one that started in 2024, is the only one in phase 2/3, reaches primary completion later than 6 of the 12 other live ones, and was the 54th registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →10 of the 65 studies in Heart Arrest with a site in Canada are open now. Recruiting first, the newest first:
Columbia University · Sites in Canada, United States, Brazil and 2 more countries
Ages 18+
Laval University · Sites in Canada
University of Calgary · Sites in Canada
Johns Hopkins University · Sites in Canada, United States
Ages 18+ · Healthy volunteers
KidSIM Simulation Program · Sites in Canada, United States
Ages 18–60 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 1 Day to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 5 · Phase 4 1
First in 1992; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 284 is above the median of 100 across 519 interventional studies indexed under Heart Arrest.
Median enrollment 246 across the 46 interventional studies, 793 across the 19 observational. Of the 44 that completed or were terminated, 20 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 65 have an industry lead sponsor. The 10 most frequent:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the lead sponsor of 332 studies on the registry; 137 are open to participants now.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's has 1 study filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
2 of the studies in Heart Arrest with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07829887University of CalgaryCerebral Oximetry in Management of Post Cardiac Arrest | 2027-02 |
| NCT07484828Laval UniversityEvaluation of Acid-base Disorders and Ventilation Settings in Cardiogenic Shock and Post-cardiac Arrest Patients: Comparison With VentilO Algorithm | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 65 studies in Heart Arrest with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a pragmatic, two-arm, open-label, prospective stepped-wedge cluster quasi randomized control trial (SW-CRCT) looking to evaluate early intramuscular (IM) epinephrine in the management of pediatric out-of-hospital cardiac arrest (POHCA).
IM epinephrine may provide a more efficient means of administering the initial epinephrine dose (versus IV/IO administration) to a child experiencing pediatric out of hospital cardiac arrest (POHCA) with no greater risk of harm. In so doing, this may improve the short- and long-term outcomes of these patients. There is an abundance of literature detailing the risk/benefit profile of IM epinephrine use in anaphylaxis; however, there is no human data on this topic as it relates to cardiac arrest. Important knowledge gaps include whether the use of IM epinephrine via autoinjector and/or pre-filled syringe leads to faster administration of the initial doses of epinephrine without delaying time to definitive epinephrine (via IV/IO) and the impact on time to initial and sustained return of spontaneous circulation (ROSC). This trial will be the first to examine the role of IM epinephrine via autoinjector/pre-filled syringe in POHCA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All POHCA events will be handled per standard of care of epinephrine administration via intravenous or intraosseous (IV/IO) based on patient estimated weight.
POHCA events will be handled per standard of care, however, first dose epinephrine administration will be via intramuscular (IM) autoinjector and/or pre-filled syringes. Dosing will be dependent on weight as follows: * 3-\<5kg=0.3mg IM epinephrine * 5-\<10kg=0.5mg IM epinephrine * 10-\<20kg=1.0mg IM epinephrine * 20-\<30kg=2.0mg IM epinephrine * 30kg=3.0mg IM epinephrine
Drug: Epinephrine Injection
Epinephrine administered via sterile epinephrine injection USP, by 0.3mg or 0.5mg epinephrine auto-injector(s) and/or pre-filled syringe (exact dose).
Time to initial return of spontaneous circulation (ROSC)
The primary outcome will be the time to initial ROSC. The investigator will compare time to initial ROSC between the standard of care and intervention periods.
Time frame: At time of event
Return of spontaneous circulation
Whether return of spontaneous circulation is achieved or not
Time frame: At time of event
Time to sustained ROSC
Time to sustained ROSC will be calculated from the time that paramedics arrive on scene to the time that sustained ROSC, defined as chest compressions not required for 20 minutes with persistent signs of circulation, is achieved.
Time frame: At time of event
Survival
Survival to emergency department transfer to pediatric critical care unit (PCCU), if applicable: admitted to PCCU from external ED
Time frame: From time of event to ED admission
Survival - comparison between both arms
Survival to hospital admission will be compared between standard of care and intervention periods
Time frame: From time of event to hospital admission
PCCU/Hospital length of stay
PCCU and hospital length of stay will be calculated from time of admission to the PCCU/hospital and time to discharge from PCCU/hospital, if applicable, between standard of care and intervention periods
Time frame: From time of hospital/PCCU admission to discharge, up to 1 year
Survival to hospital discharge
Survival to hospital discharge will be compared between standard of care and intervention periods
Time frame: Dependent on course of hospital stay, up to 1 year
Post POHCA survival
Survival at 6 months and 12 months post-POHCA will be compared between standard of care and intervention periods
Time frame: Dependent on survival at 6 and 12 month period post POHCA event
Neurological status
The investigator will compare PCPC scores at discharge, 6- and 12-months post-POHCA between the standard of care and intervention periods
Time frame: From time of discharge and 6 and 12 months post POHCA event
Life Impact and Pediatric Quality of Life assessments
Life Impact assessment between 6 and 12 months: the investigator will use the Pediatric Quality of Life (PEDSQoL, Pediatrics Quality of Life) assessment tool at 6- and 12-months post-POHCA in all survivors and compare between standard of care and intervention periods. The score ranges from 0-100, with higher scores indicating better outcome.
Time frame: 6 and 12 months post POHCA event
Life Impact and Pediatric Quality of Life assessments
Life Impact assessment between 6 and 12 months: the investigator will use the Daily Activities Scale at 6- and 12-months post-POHCA in all survivors and compare between standard of care and intervention periods. This scale is a subscore of the PEDSQoL tool with scores ranging from 0-100, with higher scores indicating better outcome.
Time frame: 6 and 12 months post POHCA event
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Jan 2028, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epinephrine
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's →